Imaging diabetic cardiomyopathy in a type 1 diabetic rat model using 18F-FEPPA PET

IF 3.6 4区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear medicine and biology Pub Date : 2024-01-01 DOI:10.1016/j.nucmedbio.2024.108878

Hsin-Hua Hsieh , Pei-An Chu , Yu-Hsin Lin , Yu-Chieh Jill Kao , Yi-Hsiu Chung , Shih-Ting Hsu , Jia-Min Mo , Chun-Yi Wu , Shin-Lei Peng

{"title":"Imaging diabetic cardiomyopathy in a type 1 diabetic rat model using 18F-FEPPA PET","authors":"Hsin-Hua Hsieh , Pei-An Chu , Yu-Hsin Lin , Yu-Chieh Jill Kao , Yi-Hsiu Chung , Shih-Ting Hsu , Jia-Min Mo , Chun-Yi Wu , Shin-Lei Peng","doi":"10.1016/j.nucmedbio.2024.108878","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Diabetic patients often experience chronic inflammation and fibrosis in their cardiac tissues, highlighting the pressing need for the development of sensitive diagnostic methods for longitudinal assessment of diabetic cardiomyopathy. This study aims to evaluate the significance of an inflammatory marker known as translocator protein (TSPO) in a positron emission tomography (PET) protocol for longitudinally monitoring cardiac dysfunction in a diabetic animal model. Additionally, we compared the commonly used radiotracer, <sup>18</sup>F-fluoro-2-deoxy-<span>d</span>-glucose (<sup>18</sup>F-FDG).</p></div><div><h3>Methods</h3><p>Fourteen 7-week-old female Sprague-Dawley rats were used in this study. Longitudinal PET experiments were conducted using <sup>18</sup>F-<em>N</em>-2-(2-fluoroethoxy)benzyl)-<em>N</em>-(4-phenoxypyridin-3-yl)acetamide (<sup>18</sup>F-FEPPA) (<em>n</em> = 3), the TSPO radiotracer, and <sup>18</sup>F-FDG (n = 3), both before and after the onset of diabetes. Histological and immunohistochemical staining assays were also conducted in both the control (<em>n</em> = 4) and diabetes (n = 4) groups.</p></div><div><h3>Results</h3><p>Results indicated a significant increase in cardiac tissue uptake of <sup>18</sup>F-FEPPA after the onset of diabetes (<em>P</em> < 0.05), aligning with elevated TSPO levels observed in diabetic animals according to histological data. Conversely, the uptake of <sup>18</sup>F-FDG in cardiac tissue significantly decreased after the onset of diabetes (P < 0.05).</p></div><div><h3>Conclusion</h3><p>These findings suggest that <sup>18</sup>F-FEPPA can function as a sensitive probe for detecting chronic inflammation and fibrosis in the cardiac tissues of diabetic animals.</p></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"128 ","pages":"Article 108878"},"PeriodicalIF":3.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0969805124000040/pdfft?md5=dc8dde21cd5f9959b65d3c8fb5d5d437&pid=1-s2.0-S0969805124000040-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805124000040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Diabetic patients often experience chronic inflammation and fibrosis in their cardiac tissues, highlighting the pressing need for the development of sensitive diagnostic methods for longitudinal assessment of diabetic cardiomyopathy. This study aims to evaluate the significance of an inflammatory marker known as translocator protein (TSPO) in a positron emission tomography (PET) protocol for longitudinally monitoring cardiac dysfunction in a diabetic animal model. Additionally, we compared the commonly used radiotracer, ¹⁸F-fluoro-2-deoxy-d-glucose (¹⁸F-FDG).

Methods

Fourteen 7-week-old female Sprague-Dawley rats were used in this study. Longitudinal PET experiments were conducted using ¹⁸F-N-2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide (¹⁸F-FEPPA) (n = 3), the TSPO radiotracer, and ¹⁸F-FDG (n = 3), both before and after the onset of diabetes. Histological and immunohistochemical staining assays were also conducted in both the control (n = 4) and diabetes (n = 4) groups.

Results

Results indicated a significant increase in cardiac tissue uptake of ¹⁸F-FEPPA after the onset of diabetes (P < 0.05), aligning with elevated TSPO levels observed in diabetic animals according to histological data. Conversely, the uptake of ¹⁸F-FDG in cardiac tissue significantly decreased after the onset of diabetes (P < 0.05).

Conclusion

These findings suggest that ¹⁸F-FEPPA can function as a sensitive probe for detecting chronic inflammation and fibrosis in the cardiac tissues of diabetic animals.

Abstract Image

查看原文本刊更多论文

利用 18F-FEPPA PET 对 1 型糖尿病大鼠模型中的糖尿病心肌病进行成像

目的糖尿病患者的心脏组织经常出现慢性炎症和纤维化，因此迫切需要开发灵敏的诊断方法对糖尿病心肌病进行纵向评估。本研究旨在评估正电子发射断层扫描（PET）方案中的炎症标记物转运蛋白（TSPO）对纵向监测糖尿病动物模型心功能障碍的意义。此外，我们还比较了常用的放射性示踪剂--18F-氟-2-脱氧-d-葡萄糖（18F-FDG）。方法本研究使用了 14 只 7 周大的雌性 Sprague-Dawley 大鼠。在糖尿病发生之前和之后，使用 18F-N-2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide (18F-FEPPA) (n = 3)、TSPO 放射性示踪剂和 18F-FDG (n = 3) 进行了纵向 PET 实验。结果结果表明，糖尿病发病后，心脏组织对 18F-FEPPA 的摄取量显著增加（P <0.05），这与组织学数据显示的糖尿病动物体内 TSPO 水平升高一致。结论：这些研究结果表明，18F-FEPPA 可作为检测糖尿病动物心脏组织慢性炎症和纤维化的灵敏探针。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear medicine and biology 医学-核医学

CiteScore

6.00

自引率

9.70%

发文量

479

审稿时长

51 days

期刊介绍： Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.